R&D Focus: Four ways the biopharmaceutical industry leads in delivering new treatments and cures
By Andrew Powaleny | December 9, 2019
In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases,...
Read More
New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018
By Holly Campbell | December 6, 2019
According to new data from the National Health Expenditures (NHE), retail medicine prices declined by 1% and retail medicine spending grew just 2.5% in 2018. To put that in context, hospital...
Read More
New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines
By Nicole Longo | December 5, 2019
The House of Representatives has spent much of this fall focused on Speaker Pelosi’s drug pricing bill, H.R.3, but a recent survey of nearly 2,000 registered voters confirms that H.R.3 is not the...
Read More
Guest post: H.R.3 is the wrong approach to help patients like me
By Guest Contributor | November 26, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Speaker Pelosi’s drug pricing plan could result in 56 fewer new medicines over 10 years
By Juliet Johnson | November 21, 2019
A new analysis from economic consulting firm Vital Transformation shows that Speaker Nancy Pelosi’s drug pricing plan, H.R.3, could result in at least 56 fewer innovative medicines for patients...
Read More
Pelosi’s radical plan would leave patients with sickle cell disease behind
By Tom Wilbur | November 14, 2019
Sickle cell disease (SCD) is the most commonly inherited genetic blood disorder, affecting nearly 100,000 children and adults in the United States. Three million Americans carry the sickle cell...
Read More
R&D Focus: It takes an ecosystem to deliver innovative new therapies
By Richard Moscicki, M.D. | November 14, 2019
We are living in a new era of medicine where innovations are transforming our ability to attack the cause of a disease, not just the symptoms. Today, concepts, such as cell and gene therapies, ...
Read More
PhRMA submission to 2020 National Trade Estimate Report: Urgent action required to protect U.S. biopharmaceutical innovation
By Douglas Petersen | November 8, 2019
International trade policy plays a critical role in ensuring that the U.S. biopharmaceutical industry can continue to develop and provide both American and international patients with access to...
Read More
Pelosi’s radical plan would leave patients with rare pediatric diseases behind
By Tom Wilbur | November 7, 2019
There are about 7,000 rare diseases and half of these affect children. According to the National Institutes of Health (NIH), 30 million Americans, or 10 percent of the population, have one of the...
Read More
Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter
By Guest Contributor | November 7, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Medicare Monday (100)
340B Spotlight (42)
Cost & Consequence (0)
